
<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Philanthropy Australia</provider_name><provider_url>https://www.philanthropy.org.au</provider_url><author_name>Dee Rudebeck</author_name><author_url>https://www.philanthropy.org.au/author/dee-rudebeck/</author_url><title>How impact investment is making a difference in global health equity - Philanthropy Australia</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="z6uNB5mwIO"&gt;&lt;a href="https://www.philanthropy.org.au/news-and-stories/how-impact-investment-is-making-a-difference-in-global-health-equity/"&gt;How impact investment is making a difference in global health equity&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.philanthropy.org.au/news-and-stories/how-impact-investment-is-making-a-difference-in-global-health-equity/embed/#?secret=z6uNB5mwIO" width="600" height="338" title="&#x201C;How impact investment is making a difference in global health equity&#x201D; &#x2014; Philanthropy Australia" data-secret="z6uNB5mwIO" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
&lt;/script&gt;
</html><description>Impact investing is playing a critical and growing role in the development of medicines to treat &#x2018;neglected diseases&#x2019; affecting the world&#x2019;s poorest and most underserved peoples. These medicines would not otherwise be developed by the pharmaceutical industry, which is primarily driven by financial returns. Here, Mark Sullivan AO, founder and managing director of Medicines Development for Global Health, an Australian biopharmaceutical not-for-profit, describes how this finance model is supporting the development of Moxidectin &#x2013; a potential gamechanger for the WHO&#x2019;s roadmap to ending river blindness by 2030.</description><thumbnail_url>https://www.philanthropy.org.au/wp-content/uploads/2024/02/Mark-Sullivan-MDGH-MD.png</thumbnail_url></oembed>
